After 3 years of co-design with stakeholders and EU regulatory partners, the European Medicines Agency's Regulatory Science to 2025 strategy has been finalized. Here, we highlight the core recommendations that stakeholders deem most significant to advance evidence generation.
- i18 - "Health: Government Policy; Regulation; Public Health"
- o30 - "Technological Change; Research and Development; Intellectual Property Rights: General"
- Intellectual Property
- European Union